Venlafaxin insättningssymtom

Venlafaxine

Antidepressant medication

Pharmaceutical compound

Pronunciation
VEN-lə-FAK-seen
Trade namesEffexor, others[1]
AHFS/Monograph
MedlinePlusa
License data
Pregnancy
category
Routes of
administration		Oral
Drug classSerotonin–norepinephrine reuptake inhibitor
ATC code
Legal status
Bioavailability42±15%[2]
Protein binding27±2% (parent compound), 30±12% (active metabolite, desvenlafaxine)[6]
MetabolismExtensively metabolised by the liver,[2][6] primarily via CYP2D6[8]
MetabolitesO-desmethylvenlafaxine (ODV), see desvenlafaxine
Elimination half-life5±2 h (parent compound for immediate release preparations), 15±6 h (parent compound for extended-release preparations), 11±2 h (active metabolite)[2][6]
ExcretionKidney (87%; 5% as unchanged drug; 29% as desvenlafaxine and 53% as other metabolites)[2][6]

IUPAC name

  • (RS)[2-dimethylamino(4-methoxyphenyl)-ethyl]cyclohexanol

CAS Number
PubChemCID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashbo
Utredningen som riktar sig mot hälso- samt sjukvårdspersonal, besitter utformats utefter tillgänglig litteratur och tillgångar vid tidpunkten för analys. Innehållet inom utredningen uppdateras inte. Hälso- och sjukvårdspersonal är ansvarig för hur de använder informationen nära rådgivning alternativt behandling från patienter.


Utsättningssymtom från venlafaxin



Fråga: Jag har ett patient liksom haft venlafaxin under flera år samt nu besitter vi trappat ut läkemedlet pga utebliven effekt. beneath egentligen bota nedtrappningen (som skett inneliggande på sjukhus) har patienten haft huvudvärk, yrsel, illamående och ”stötar igenom kroppen”, vilket tolkats som utsättningssymptom. Nu existerar venlafaxin exponerad helt sedan en sju dagar men symptomen finns kvar. Jag fråga vad senaste forskningen säger om venlafaxins nedtrappning, utsättningssymptom och eventuell behandling från dessa?

Svar:
Sammanfattning

The rates of withdrawal symptoms from both RCT and open trials range from 23 to 78% after discontinuation of venlafaxine.
According to FASS the fara of withdrawal symptoms may be dependent on several factors, including the duration and dos of therapy and the rate of dose reduction [1]. Published studies an

  • venlafaxin insättningssymtom

    • Venlafaxine

    Boxed Warning

    Suicidality and antidepressant drugs:

    Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of venlafaxine or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Venlafaxine is not approved for use in pediatric patients.

    Dosage Forms

    Excipie